PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	116-124	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27	
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	116-124	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33	
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	136-144	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27	
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	136-144	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33